HHM Wealth Advisors LLC increased its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 200.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 225 shares of the financial services provider’s stock after purchasing an additional 150 shares during the quarter. HHM Wealth Advisors LLC’s holdings in iShares Biotechnology ETF were worth $30,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in iShares Biotechnology ETF in the third quarter valued at $29,000. Highline Wealth Partners LLC bought a new stake in iShares Biotechnology ETF in the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF during the 3rd quarter valued at about $36,000. Modus Advisors LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter valued at about $41,000. Finally, Crews Bank & Trust bought a new position in iShares Biotechnology ETF in the 4th quarter worth about $44,000. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Performance
Shares of NASDAQ IBB opened at $137.85 on Tuesday. The firm’s 50-day simple moving average is $136.33 and its 200 day simple moving average is $141.50. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- How to Invest in Small Cap Stocks
- Using the MarketBeat Stock Split Calculator
- These Are the Dividend Stocks Insiders Bought in January
- Do ETFs Pay Dividends? What You Need to Know
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
